This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma

This study has been completed.
Information provided by (Responsible Party):
Steinar Aamdal, Oslo University Hospital Identifier:
First received: February 15, 2009
Last updated: October 19, 2015
Last verified: October 2015
The study induces an immune response towards the stem-cell like part of glioblastomas in combination with standard therapy. The aim is to define and characterize the feasibility, potential adverse effects of such therapy and measure time to progression and survival.

Condition Intervention Phase
Glioblastoma Brain Tumor Biological: Dendritic cell vaccine with mRNA from tumor stem cells Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma

Resource links provided by NLM:

Further study details as provided by Steinar Aamdal, Oslo University Hospital:

Primary Outcome Measures:
  • Adverse events [ Time Frame: During follow-up ]

Secondary Outcome Measures:
  • Evaluation of immunological response, time to disease progression and survival time [ Time Frame: 5 years ]

Enrollment: 20
Study Start Date: January 2009
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Dendritic cell vaccine with mRNA from tumor stem cells
    Intradermal injection of transfected dendritic cells

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Accessible volume and quality of tumor tissue for vaccine production
  • MRI after surgery with minimal tumor remnant.
  • Between 18 and 70 years of age.
  • Must have histologically confirmed glioma grade IV, and a candidate for combined radiation therapy and chemotherapy ("Stupps regimen").
  • Must be ambulatory with a ECOG performance status 0 or 1.
  • A minimum 4 weeks must have elapsed between the end of glucocorticoid treatment and beginning of vaccination.
  • Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented.

Exclusion Criteria:

  • Tumor in a localization where a modest increase in size due to reactive oedema may have a large impact on patients neurological condition.
  • Large tumor remnant after surgery.
  • History of prior malignancy other than glioma, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin and ca. cervicis stage IB.
  • Chronic active infection requiring antibiotic therapy.
  • Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.
  • Prior splenectomy.
  • Glucocorticoid treatment not possible to terminate due to autoimmune disease or increased intracranial pressure.
  • Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions.
  • History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis- dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome.
  • Chemotherapy or other potentially immune-suppressive therapy that has been administered within 4 weeks prior to vaccination.
  • Pregnancy or lactation.
  • Any reason why, in the opinion of the investigator, the patient should not participate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00846456

Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Steinar Aamdal, MD, PhD Department of Clinical Cancer Research, Rikshospitalet
Study Director: Iver A Langmoen, MD, PhD Dept of Neurosurgery, Ulleval University Hospital
Study Director: Gunnar Kvalheim, MD, PhD Dept of cellular therapy, Rikshospitalet HF
Study Director: Gustav Gaudernack, PhD Inst. of Immunotherapy, Rikshospitalet HF
Study Director: Knut Lote, MD, PhD Dept. of oncology, Rikshospitalet HF
Study Director: Jon Berg-Johnsen, MD, PhD Dept. of Neurosurgery, Rikshospitalet HF
Study Director: Carl Langberg, MD, PhD Dept of oncology, Ulleval University Hospital
Study Director: Marta Nyakas, MD Dept. of Clinical Cancer Research, Rikshospitalet HF
Study Director: Einar O Vik-Mo, MD Dept of Neurosurgery, Ulleval University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Steinar Aamdal, Oslo University Hospital Identifier: NCT00846456     History of Changes
Other Study ID Numbers: DC-CAST-GBM
Study First Received: February 15, 2009
Last Updated: October 19, 2015

Keywords provided by Steinar Aamdal, Oslo University Hospital:
Tumor setm cell

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017